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ARTICLE INFO                                         ABSTRACT
 
 
 
A cancer biomarker
be a molecule secreted by a
Background
molecules Cytokeratin 20, Cytokeratin 17, Cytokeratin 10 and Anillin as tumor specific markers to 
rapidly detect cancer
Materials and Methods
synthesized cDNA.  Specific primers were synthesized for the biomarkers Cytokeratin 10, 
Cytokeratin 20 Cytokeratin 17 and Anillin
using mMLuv reverse transcriptase. 
Results
while the expression of cytokeratin 10 did not show much expression 
20 and Anillin showed better expression in both cell lines. 
Conclusion
genes as potential makers for detection of cancer
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INTRODUCTION 
 
Cancer is a generic term for a large group of diseases that can 
affect any part of the body. Other terms used are malignant 
tumors and neoplasms. One defining feature of cancer is the 
rapid creation of abnormal cells that grow beyond their usual 
boundaries, and which can then invade adjoining parts of the 
body and spread to other organs. This process is referred to as 
metastasis. Carcinogenesis is a multistep process featuring the 
accumulation of several genetic alterations, including the 
activation of oncogenes and the inactivation of tumor
suppressor genes. The International Agency for Research on 
Cancer (IARC) estimates that there were some 12 m
cases in 2009 with more than 7 million deaths. WHO (World 
Health Organization) estimates that about one
cancer burden could be decreased if cases we
treated early. Cancer cells display a broad spectrum of genetic 
alterations that include gene rearrangements, point mutations, 
and gene amplifications, leading to disturbances in molecular 
pathways regulating cell growth, survival, and metastasis. 
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 refers to a substance or process that is indicative of the presence of
 tumor or a specific response of the body to the presence of cancer.
: The aim of the present study is to investigate the feasibility and potential of the 
. 
: The expression of biomarkers was analyzed by preparing RNA and 
 and semi quantitative gene expression was carried out 
 
: All the three biomarkers showed an enhanced expression compared with normal fibroblasts 
 
: All the biomarkers showed comparatively good expression 
. 
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When such changes manifest in majority of patients with a 
specific type of tumour, these can be used as biomarkers for 
detection and developing targeted therapies, 
responses to various treatments
2010). The National Cancer Institute defines a biomarker as “a 
biological molecule found in the blood, other body fluids, or 
tissues that is a sign of a normal or abnormal pro
condition or disease. The ideal biomarker should screen for the 
disease and its progression, identify high
predict recurrence, and monitor response to treatments. It 
should be economical, consistent, non
accessible, and quickly quantifiable. 
2013) 
 
Tumor Markers comprise a wide spectrum of 
biomacromolecules synthesized in excess concentration by a 
wide variety of neoplastic cells. The appearance of tumor 
marker and their concentration 
growth of malignant tumors in patients. An ideal tumor marker 
should be highly sensitive, specific, and reliable with high 
prognostic value, organ specificity and it should correlate with 
tumor stages. Many tumor markers have
clinical relevance in monitoring efficacy of different modes of 
therapies during entire course of illness in cancer patients.
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Compared to procedures such as radiology, cytology and 
endoscopy, the use of biomarkers as cancer screening tests 
have several advantages (Duffy et al., 2001). Biomarkers can 
be measured in biological fluids such as blood and urine that 
can be obtained with minimal inconvenience to subjects 
undergoing screening. This in turn should lead to high 
compliance rates. Biomarkers are valuable drug development 
tools that provide more accurate or more complete information 
regarding disease progression. One of the most recently 
investigated markers is Cytokeratin 20 (CK 20), which was 
first characterized by Moll et al., 1992. In tumor condition the 
CK20 level increases. CK-20 positivity was seen in a vast 
majority of adenocarcinomas of the colon, mucinous ovarian 
tumors, transitional-cell and Merkel-cell carcinomas and 
frequently also in adenocarcinoma of the stomach, bile system, 
and pancreas. Most squamous cell carcinomas in general and 
most adenocarcinomas from other sites (breast, lung, 
endometrium), nonmucinous tumors of the ovary, and small-
cell lung carcinomas were essentially or completely negative 
(Roland Moll et al., 1992). The expression of CK17 was 
restricted to pancreatic ductal carcinoma, the ampullary 
carcinoma of pancreatobiliary origin, and intrahepatic 
cholangiocarcinoma.Increased expression of keratins in 
endothelial cells, such as keratin 17, may contribute to the 
angiogenesis induced by HepG2 cells (Yong Xu et al., 2004). 
The advantages of using Biomarkers are 
 
 For many biomarkers, automated assays are available, thus 
allowing the processing of large numbers of samples in a 
relatively short period of time. 
 Tests for biomarkers provide quantitative results with 
objective endpoints.   
 Assays for biomarkers are relatively cheap. 
 Early detection of cancer is based on the observation that 
treatment is more effective when cancer is detected earlier. 
Utilizing the potential of tumor markers in devising rapid 
and sensitive diagnostic tests is therefore of primary 
importance. 
 
Keratins 
 
Keratins are proteins ranging from 40KDa to 68 KDa are 
known to form intermediate filaments of 8-10 nm in diameter. 
Keratins are remarkably diverse, highly resistant and the most 
conserved cytoskeletal proteins present in all types of 
epithelial cells. The composition of keratin filaments ranges 
from a few polypeptides to 19 different polypeptides ranging 
from 40KDa to 68 KDa. There may be variations in keratin 
expression compared to that in normal tissue, depending on the 
degree of differentiation of epithelial tumors. This property of 
keratins allows their effective use, in combination with other 
changes, as tumor markers for malignant transformation in 
epithelioid tumors. Keratins as tumor markers have two main 
applications: (i) in distinguishing epithelial from nonepithelial 
tumors, and (ii) in distinguishing the type of epithelial tumor. 
The degree of keratin expression in tumors is remarkably high. 
 
Cytokeratin 20 
 
Cytokeratin 20 is 46kDa intermediate filament protein that has 
been identified with expression primarily restricted to gastric 
and intestinal epithelium, urothelium, and Merkel cells. 
Cytokeratin 20 is a unique type I keratin that is expressed in 
adenocarcinomas of the colon, stomach, pancreas and bile 
system. It is also expressed in mucinous ovarian tumors, 
transitional cell carcinomas of the urinary tract, and Merkel 
cell carcinomas (Amiram Fishman et al., 2000). CK20 is 
essentially non-reactive in squamous cell carcinomas and 
adenocarcinomas of the breast, lung, and endometrium, as well 
as non-mucinous tumors of the ovary and small cell 
carcinomas. 
 
Cytokeratin 17 
 
 Cytokeratin 17 a type I cytokeratin, is found in nail beds, hair 
follicles, sebaceous glands, and other epidermal appendages. 
CK17 was restricted to pancreatic ductal carcinoma, the 
ampullary carcinoma of pancreatobiliary origin, and 
intrahepatic cholangiocarcinoma. 
 
Cytokeratin 10 
 
Keratin, type I cytoskeletal 10 is a protein that in humans is 
encoded by the KRT1gene. Keratins are heteropolymeric 
structural proteins which form the intermediate filament. These 
filaments, along with actin microfilaments and microtubules, 
compose the cytoskeleton of epithelial cells. This gene encodes 
a member of the type I (acidic) cytokeratin family, which 
belongs to the superfamily of intermediate filament (IF) 
proteins. 
 
Anillin  
 
Anillin  is an actin-binding protein that can bind septins and is 
a component of the cytokinetic ring. Anillin is expressed 
ubiquitously but with variable levels of expression, being 
highest in the central nervous system. Reports indicate that 
septins have a role in various disease states including cancer. 
The median level of anillin mRNA expression was not only 
shown to be higher in tumors compared to normal tissues but 
also increase as disease progressed. Anillin is expressed 
ubiquitously but with variable levels of expression, being 
highest in the central nervous system. The median level of 
anillin mRNA expression was higher in tumors than normal 
tissues except in the central nervous system where anillin 
mRNA levels were lower in tumors. (Peter Hall  et al., 2005). 
To establish alternative approaches with higher sensitivity, 
polymerase chain reaction (PCR)-based assays that have been 
used. PCR techniques are highly sensitive and clinically useful 
for detecting cancer markers in circulating tumor cells (Chie 
Suzuki et al., 2005). The aim of the present study is to 
investigate the feasibility and potential of the molecules 
Cytokeratin 20, Cytokeratin 17, Cytokeratin 10 and Anillin as 
tumor specific markers to rapidly detect cancer by semi 
quantitative  PCR. This will not only be of great significance 
in developing a reliable diagnostic method for screening 
multiple cancers, but also serve as valuable disease prognosis 
indicators and potential vaccine/ drug targets. 
 
MATERIALS AND METHODS 
 
The cell lines SW480 and HCT116, ATCC strains were 
provided by IISc, Bangalore. Afibroblast, fetal fibroblasts were 
established post biopsy in the Cell Culture Lab, ENZENE 
Biosciences pvt ltd All the cell lines were grown in monolayer 
in appropriate media DMEM (Hyclone) supplemented with 
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10% FCS (Gibco) andwere maintained at 37°C in an 
atmosphere of humidified airwith 5% CO2. Trypsin EDTA 
(Gibco) was used to detach the monolayer for subculturing or 
for preparing cells for experiments.. After 72 hours total RNA 
was isolated by using the RNeasy mini Kit (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions 
 
 SW480- Human colorectal adenocarcinoma cells 
 HCT116-Humancolorectal carcinoma cells 
 Afibroblast- Human normal epithelial cells 
 
These cells were maintained in DMEM-10% [10% FCS] 
+antibiotics. SW480, HCT116 are colorectal carcinoma cells, 
whereas Afibroblast is a normal epithelial cell. Approximately 
1 million cells of each cell lines were suspended in 200µl RLT 
Buffer each for RNA extraction according to [QIAGEN RNA 
extraction kit].The RNA extracted was run on 1.2% 
Formaldehyde agarose gel. 
 
Formaldehyde agarose gel electrophoresis 
 
For gel preparation (1.2%) 0.24g Agarose was added to 20ml 
1XFAbuffer, 360µl formaldehyde and 3µl ethidium bromide. 
Preparation of 10 x FA gel buffer is given in (Table 1) 
 
cDNA PREPERATIONS 
 
cDNAs were synthesized by M-MLV reverse transcriptase 
(Fermentas, Lithuania) kit. cDNA reaction mixture as follows 
(Table 2). The total volume of 20µl is incubated for 60 min at 
420C and the reaction is terminated by heating at 700c for 5 
min. 
 
Primers 
 
The following primers were designed after having taken into 
consideration the Tm value and molecular weight primers has 
been designed using NCBI tools (Table 3). 
 
Primer Synthesis and reconstitution 
 
The primers for Cytokeratin 20, Cytokeratin 17, Cytokeratin10 
and Anillin whose sequences have been given in section3.2.6 
were designed and commercially synthesized. The primers 
were reconstituted in TE buffer at a concentration of 
200picomoles/µl, aliquoted into 20picomoles/µl aliquots and 
frozen at -200C. 
 
Standardization of PCR conditions with ACTIN 
 
About 1 µl cDNA was taken and PCR was performed in the 
final volume of 20µl, containing 1X reaction buffer, 10mM 
dNTP mix, 1.5U Taq polymerase, 20picomoles of primer. The 
following PCR conditions were followed, initial denaturation 
at 940 C for 4 min, followed by denaturation at 940 C for 30 
sec, annealing at 600 C for 30 sec, extension at720C for 40 sec, 
and final extension at720 C for 3 min. 
 
PCR for the Biomarkers 
 
cDNAs were synthesized by M-MLV reverse transcriptase 
(Fermentas, Lithuania) and subjected  to polymerase chain 
reaction (PCR) initially or actin normalization then the specific 
primers for  Anilin,Cytokeratin10,Cytokeratin 17, Cytokeratin 
20,  were checked for gene expression . PCR conditions for 
amplification were:  95°C for 3 min, 95°C for 30sec min and 
58°C extension for 30sec and 72°C extension 1min for 30 
cycles. The PCR products were visualized using1.2% agarose 
gel electrophoresis and staining with ethidium bromide 
 
RESULTS 
 
Cell line establishment and maintenance 
 
Biopsy was obtained from healthy donors and washed 
repeatedly in Antibiotic - Antimycotic (A+A) solution and 
treated with 0.3% collagenase overnight at 40C. The cell 
suspension was then directly seeded onto culture dishes and 
incubated at 370C. After sufficient growth, the cells were 
trypsinized, washed, and expanded or cryopreserved after 
suspension in freezing medium  SW480, HCT 116  and 
Afibroblasts were grown to confluence , trypsinized ,washed in 
PBS and used for subsequent RNA isolation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RNA extraction 
 
Total RNA was extracted from each of the three cell types 
(two cancerous and one normal).The extracted RNA was 
checked on a 1.2%formaldehyde gel (Fig. 1). The results 
indicate that the total RNA was successfully isolated from the 
three different cell types and were therefore used to synthesize 
cDNA.   
 
 
 
Fig. 1. Qualitative Analysis of RNA on 1.5% formaldehyde 
Agarose gel 
 
Standardization of cDNA synthesis pcr conditions for actin 
 
Total RNA isolated from the 3 cell types, was then used to 
synthesize cDNA. 
Table 1. Preparation of 10 X FA gel buffer 
 
200mM MOPS 
50mM        sodium acetate 
10mM       EDTA 
pHwas adjusted to 7.0 with NaOH 
Table 2. CDNA synthesis reaction protocol 
 
Total RNA  6 µl(1.5ug) 
OligodT primer 1µl 
DEPC treated water 5µl 
5X Reaction buffer  4µl 
dNTPS 2µl 
RNase Inhibitor 1µl 
Reverse Transcriptase 1 µl 
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The synthesized cDNA was used as a template for the 
standardization of PCR conditions using the actin primers. 
Amplification (250 bp) was observed (Fig. 2) in all the cell 
lines under optimized PCR conditions. 
 
 
LaneM:100bp marker 
Lane1-3-cDNA optimization with β-actin primers (Afibro,SW480,HCT116) 
 
Fig. 2. cDNA optimization for RNA samples 
 
 
Lane M:100bp marker 
Lane1-3-Anilin amplification 270bp (Afibro,SW480,HCT116) 
Fig. 3. Semi quantitative analysis of RNA expression using Anilin 
marker 
 
PCR for the biomarkers 
 
After actin normalization same amount of cDNA was taken 
then the specific primers for all the three markers was used for 
expression check an amplification of Anilin(270bp) (Fig 3), 
Cytokeratin 10(150bp) (Fig 4), Cytokeratin 17(180bp) (Fig5), 
Cytokeratin 20(370bp) (Fig 6) was observed when PCR 
products were visualized using1.2% agarose gel 
electrophoresis. 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
LaneM:100bp marker 
Lane1-3-Cytokeratin10amplification150bp (Afibro,SW480,HCT116) 
Fig 4. Semi quantitative analysis of  RNA expression using 
Cytokeratin 10 (CK10) marker 
 
 
LaneM:100bp marker 
Lane1-3-Cytokeratin17amplification180bp (Afibro, SW480, HCT116) 
  
Fig. 5. Semi quantitative analysis of  RNA expression using 
Cytokeratin17 (CK17) marker 
 
 
LaneM:100bp marker 
Lane1-3-Cytokeratin 20 amplification370bp(HCT116, Afibro,SW480) 
 
Fig. 6. Semi quantitative analysis of  RNA expression using 
Cytokeratin 20(CK20 ) marker 
 
Table 3. Primers used for semi qualitative gene expression for the biomarkers includes primer sequences  andannealing temperatures 
 
 
Sl.No Primer Name Forward primer Reverse primer Annealing temperature Tm
1 Actin 5’TCCATAATGAAGTGTGATGT3’ 5’GGACCTGACTCGTCATACTC3’ 60
0
C
2 Anillin 5’TGGCTAATTGTACCAGTCGTCAGA3' 5’AGGCTTTCCAATAGGTTTGTAGCA3’ 58
0
C
3 Cytokeratin 10 5’TGGTTCAATGAAAAGAGCAAGGA 3’ 5’GGGATTGTTTCAAGGCCAGTT 3’ 60
0
C
4 Cytokeratin 17 5’CATGCAGGCCTTGGAGATAGA 3’           5’CACGCAGTAGCGGTTCTCTGT 3’ 59
0
C
5 Cytokeratin 20 5’CAGACACACGGTGAACTATGG3’  5’GATCAGCTTCCACTGTTAGACG3’ 60
0
C
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DISCUSSION 
 
Until superior therapeutic treatments are developed to prevent, 
treat and cure cancer, the best means of reducing mortality and 
morbidity in a disease this complex is early detection and 
diagnosis. In the major solid cancer types such as lung, breast, 
colon and prostate, long-term survival rates drop precipitously 
once metastasis has occurred diagnostic measurement of 
cancer disease progression is essential to successful disease 
management. For these reasons, development of new and 
effective biomarkers for cancer detection and diagnosis is 
central to the cancer problem. Based on literature survey, we 
identified the markers Cytokeratins 1017, 20 and Anillin as 
potentially new biomarker candidates which can be used in 
developing a reliable, sensitive and rapid diagnostic test for 
screening multiple tumors.  Our results indicated that levels of 
Cytokeratin 17, 20 were higher in both the cancerous cell line 
compared to the normal cells. Cytokeratin 10 levels were 
higher in only one of the two cancerous cell lines. This could 
be because the origin and nature of the two cell line were 
different, though further tests need to be done to confirm this. 
If these results prove to be consistent, then there is a possibility 
of using Cytokeratin 10 as a specific tumor marker for 
distinguishing between different types of colorectal carcinoma. 
Our results also show that Anillin levels were also significantly 
higher in two cancerous cell and therefore can be used as a 
tumor marker.   
 
Conclusion 
 
In conclusion we have identified Anillin, Cytokeratin17 and 
Cytokeratin20 as general  tumor markers and Cytokeratin 10 as 
a potential marker for specific types of carcinomas. While 
these results need to be substantiated, it opens up the 
possibility of using these markers in conjugation with other 
known/unknown markers for effective tumor diagnosis. While 
more and more evidence points toward a clinical relevance for 
quantification of tumor cells, patient survival will provide the 
ultimate validation of any proposed marker or combination of 
marke. 
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